Free shipping on all orders over $ 500

Polatuzumab vedotin

Cat. No. M24608
Polatuzumab vedotin Structure
Size Price Availability
100ug USD 530  USD530 Out of stock
1mg USD 1480  USD1480 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).

Chemical Information
CAS Number 1313206-42-6
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] No authors listed. Polatuzumab Vedotin

[2] Hervé Tilly, et al. N Engl J Med. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

[3] Laurie H Sehn, et al. Blood Adv. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

[4] Laurie H Sehn, et al. J Clin Oncol. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

[5] Emma D Deeks. Drugs. Polatuzumab Vedotin: First Global Approval

Related Drug-Linker Conjugates for ADC Products
SC-VC-PAB-MMAE

SC-VC-PAB-MMAE is part of a drug-linker conjugate for ADC (ADC) with anticancer activity, which consists of MMAE (a tubulin inhibitor) linked to a cleavable SC-VC-PAB linker.

DBCO-(PEG)3-VC-PAB-MMAE

DBCO-(PEG)3-vc-PAB-MMAE is an active molecule coupler (drug-linker conjugate for ADC) consisting of auristatin E attached to a DBCO-(PEG)3-vc-PAB connector. It can be used for cancer research. In addition, DBCO-(PEG)3-vc-PAB-MMAE is a click chemistry that contains a DBCO moiety and can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing an Azide moiety.

PB038

PB038 is a drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.

Val-Ala-PAB-MMAE

Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE.

Val-Ala-PABC-Exatecan

Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor).

  Catalog
Abmole Inhibitor Catalog




Keywords: Polatuzumab vedotin supplier, Drug-Linker Conjugates for ADC, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.